ABVC BioPharma (ABVC) Approved for ABV-1505 Phase II Part II in Taiwan Sites
Gentleman, Start Your Engines?
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal.
We've had...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech...
Latest article
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
